Revenue decline due to lower official PCR test prices
First written in FY2023-Q1. 3 of 5 entries say "Materialised", first in FY2023-Q2. Latest entry: FY2025.
PHC Holdings moved to the "Worse" side of this theme in 2022.
0 other companies' latest entry also says "Reframed".
- FY2025ReframedAnnual report
「Some products sold by the Group are periodically affected by reductions in reimbursement prices in response to the global trend toward policies to contain healthcare expenditure.」
The scope of the disclosure expanded from the specific event of lower revenue due to reductions in official PCR testing prices to broader price fluctuation risks arising from healthcare cost-containment policies and reimbursement price revisions, including in the BGM, CGM and Clinical Testing businesses. - FY2024MaterialisedAnnual report
「The number of PCR tests declined as the infection subsided.」
The decline in PCR testing volumes and the contraction in high-margin testing materialised as full-year revenue and profit declines in the LSIM business, with the impact of price and demand risks related to testing continuing. - FY2023-Q3MaterialisedAnnual report
「Although the number of PCR tests for COVID-19 increased year on year, revenue declined year on year due to the impact on prices of lower reimbursement rates for the tests.」
Despite the increase in testing volumes driven by the eighth wave, the overall Clinical Testing business posted lower revenue due to the impact of lower reimbursement rates. - FY2023-Q2MaterialisedAnnual report
「Although the number of PCR tests increased year on year, Healthcare Solutions revenue declined year on year due to the impact of lower prices resulting from reduced reimbursement rates for the tests.」
Despite the increase in PCR testing volumes, the impact of lower reimbursement rates materialised as lower Healthcare Solutions revenue. - FY2023-Q1First statedAnnual report
「In addition to the year-on-year decline in the number of PCR tests for COVID-19, the Healthcare Solutions business posted lower revenue year on year due to the adverse impact of the reduction in official reimbursement prices for these tests.」
The reduction in official reimbursement prices for PCR testing materialised as lower Healthcare Solutions revenue, together with the decline in testing volumes.